Motley Fool  Jun 27  Comment 
A look under the hood at AbbVie Inc., how Novartis is prepping to fight Regeneron, and can Clovis capture the lead in the PARP race?
Benzinga  Jun 26  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares have been on an uptrend since late April, adding roughly 40 percent. The run up has led to worries over whether the stock has gotten ahead of fundamentals. Bernstein downgraded Regeneron,...
Motley Fool  Jun 20  Comment 
New data suggest that Novartis may have a drug that works similarly to Eylea but requires fewer monthly eye injections per year.
Forbes  Jun 20  Comment 
The best performing sector as of midday Tuesday is the Healthcare sector, higher by 0.7%. Within that group, Regeneron Pharmaceuticals, Inc. (NASD: REGN) and Alexion Pharmaceuticals Inc. (NASD: ALXN) are two of the day's stand-outs, showing a gain...
MarketWatch  Jun 20  Comment 
Regeneron Pharmaceuticals Inc. shares surged 6.6% in midday trade Tuesday after Novartis AG released positive data for two late-stage trials comparing its eye disease drug head-to-head with Regeneron's Eylea. The drug, RTH258, met the primary...
Benzinga  Jun 15  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares are trading lower by $12.00 (2.2 percent) at $464.84 in Thursday's session. The decline may be a delayed reaction to the company's 8-K filing released before Wednesday's open. Also on...
Motley Fool  Jun 5  Comment 
Approvals of new drugs with nine-figure sales potential and a full pipeline that can fuel future growth make this stock increasingly appealing at these prices.
Motley Fool  Jun 2  Comment 
Launching two new drugs this year has sparked optimism that Regeneron Pharmaceuticals is on the upswing.


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki